Acceleron Pharma Shares Gain Ground After FDA Approves Reblozyl
November 08 2019 - 1:30PM
Dow Jones News
By Stephen Nakrosis
Shares of Acceleron Pharma Inc. (XLRN) are moving higher in
Friday's market, following the U.S. Food and Drug Administration's
announcement it had approved Reblozyl for the treatment of anemia
patients with beta thalassemia who require regular red blood cell
transfusions.
Celgene Corp. (CELG) and Acceleron are jointly developing
Reblozyl, the companies said.
At 12:55 p.m. EST, Acceleron shares had gained 6.01%, to trade
at $43.05.
Celgene shares were up 0.35%, to $109.38, following the
news.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 08, 2019 13:15 ET (18:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Oct 2024 to Nov 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Nov 2023 to Nov 2024
